var data={"title":"Alemtuzumab: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Alemtuzumab: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5580?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=alemtuzumab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Alemtuzumab: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708604\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Bone marrow suppression (Campath):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Serious, including fatal, pancytopenia/marrow hypoplasia, autoimmune idiopathic thrombocytopenia, and autoimmune hemolytic anemia can occur in patients receiving alemtuzumab. Single doses of alemtuzumab greater than 30 mg or cumulative doses greater than 90 mg per week increase the incidence of pancytopenia.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Infusion reactions (Campath):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Alemtuzumab administration can result in serious, including fatal, infusion reactions. Carefully monitor patients during infusions and withhold alemtuzumab for Grade 3 or 4 infusion reactions. Gradually escalate alemtuzumab to the recommended dose at the initiation of therapy and after interruption of therapy for 7 or more days.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Infections (Campath):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Serious, including fatal, bacterial, viral, fungal, and protozoan infections can occur in patients receiving alemtuzumab. Administer prophylaxis against <i>Pneumocystis jirovecii</i> pneumonia (PCP) and herpes virus infections.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Autoimmune effects (Lemtrada):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Alemtuzumab causes serious, sometimes fatal, autoimmune conditions, such as immune thrombocytopenia and anti-glomerular basement membrane disease. Monitor complete blood counts with differential, serum creatinine levels, and urinalysis with urine cell counts at periodic intervals for 48 months after the last dose of alemtuzumab.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Infusion reactions (Lemtrada):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Alemtuzumab causes serious and life-threatening infusion reactions. Alemtuzumab must be administered in a setting with appropriate equipment and personnel to manage anaphylaxis or serious infusion reactions. Monitor patients for 2 hours after each infusion. Make patients aware that serious infusion reactions can also occur after the 2-hour monitoring period.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Malignancy (Lemtrada):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Alemtuzumab may cause an increased risk of malignancies, including thyroid cancer, melanoma, and lymphoproliferative disorders. Perform baseline and yearly skin exams.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">REMS program (Lemtrada):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Because of the risk of autoimmunity, infusion reactions, and malignancies, Lemtrada is available only through restricted distribution under a Risk Evaluation Mitigation Strategy (REMS) Program. Call 1-855-676-6326 to enroll in the Lemtrada REMS program.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26536170\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Campath;</li>\n      <li>Lemtrada</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4663229\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Lemtrada;</li>\n      <li>MabCampath</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131201\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Anti-CD52;</li>\n      <li>\n        Antineoplastic Agent, Monoclonal Antibody;</li>\n      <li>\n        Monoclonal Antibody</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131179\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Alemtuzumab is associated with a moderate emetic potential in the oncology setting; antiemetics may be recommended to prevent nausea and vomiting (Hesketh 2017; Roila 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>B-cell chronic lymphocytic leukemia (B-CLL):</b> Campath, MabCampath [Canadian product]: IV: Gradually escalate to a maintenance of 30 mg per dose 3 times weekly on alternate days for a total duration of therapy of up to 12 weeks (Hillmen 2007; Keating 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Dose escalation is required; usually accomplished in 3 to 7 days. Single doses &gt;30 mg or cumulative doses &gt;90 mg/week increase the incidence of pancytopenia. Pretreatment (with acetaminophen 500 to 1,000 mg and diphenhydramine 50 mg) is recommended 30 minutes prior to the first dose, with dose escalations, and as clinically indicated; IV glucocorticoids may be used for severe infusion-related reactions. Administer antiviral prophylaxis (for herpetic viral infections) and Pneumocystis jirovecii pneumonia (PCP) prophylaxis; continue for at least 2 months after completion of alemtuzumab and until CD4<sup>+</sup> lymphocyte count is &ge;200/mm<sup>3</sup>. Reinitiate with gradual dose escalation if treatment is withheld &ge;7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Dose escalation:</b> Initial: 3 mg daily beginning on day 1; if tolerated (infusion reaction &le; grade 2), increase to 10 mg daily; if tolerated (infusion reaction &le; grade 2), may increase to maintenance of 30 mg per dose 3 times weekly (on alternate days) if required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>B-CLL (off-label route):</b> Campath: SubQ: Initial: 3 mg on day 1; if tolerated 10 mg on day 3; if tolerated increase to 30 mg on day 5; maintenance: 30 mg per dose 3 times weekly on alternate days for a maximum of 18 weeks (Lundin 2002) <b>or</b> 3 mg on day 1; if tolerated 10 mg on day 2; if tolerated 30 mg on day 3, followed by 30 mg per dose 3 times weekly on alternate days for 4 to 12 weeks (Stilgenbauer 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple sclerosis, relapsing:</b> Lemtrada: IV: 12 mg daily for 5 consecutive days (total 60 mg), followed 12 months later by 12 mg daily for 3 consecutive days (total 36 mg); total duration of therapy: 24 months.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Premedicate with corticosteroids (methylprednisolone 1,000 mg or equivalent) immediately prior to alemtuzumab for the first 3 days of each treatment course. Antihistamines and/or antipyretics may also be considered. Administer antiviral prophylaxis (for herpetic viral infections) beginning on the first day of treatment and continue for at least 2 months after completion of alemtuzumab or until CD4<sup>+</sup> lymphocyte count is &ge;200/mm<sup>3</sup> (whichever occurs later). In some clinical trials patients received an additional alemtuzumab 12 mg daily for 3 consecutive days 12 months later (total duration of 36 months) (CAMMS223 2008; Coles 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Aplastic anemia, refractory (off-label use):</b> Campath:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 10 mg daily for 10 days (as monotherapy); patients received a 1 mg test dose initially (Scheinberg 2012)<b> or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: 3 mg day 1, 10 mg day 2, then 30 mg/day days 3, 4, and 5 (total dose: 103 mg over 5 consecutive days; in combination with cyclosporine) (Risitano 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Autoimmune cytopenias, CLL-induced, refractory (off-label use):</b> Campath: IV, SubQ: Gradually escalate to a maintenance of 10 to 30 mg per dose 3 times weekly for 4 to 12 weeks (Karlsson 2007; Osterborg 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Graft versus host disease (GVHD), acute, steroid refractory, treatment (off-label use):</b> Campath: IV: 10 mg daily for 5 consecutive days, then 10 mg weekly on days 8, 15, and 22 if CR not achieved (Martinez 2009) <b>or</b> 10 mg weekly until symptom resolution (Schnitzler 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hemophagocytic lymphohistiocytosis, refractory (off-label use):</b> Campath: IV, SubQ: <b>Note:</b> The optimal dose and duration of therapy is not known. Median dose: 1 mg/kg (range 0.1 to 8.9 mg/kg; maximum initial dose: 3 mg) <b>divided</b> over a median of 4 days (range 2 to 10 days); refer to article for further information (Marsh 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mycosis fungoides/S&eacute;zary syndrome, advanced (off-label use):</b> Campath: IV: Initial: 3 mg, increase to 10 mg and then to 30 mg as soon as infusion-related reactions were tolerated; Maintenance: 30 mg 3 times weekly for up to 12 weeks, or until complete remission is achieved or disease progression is noted; for dosing interruptions &gt;7 days due to toxicity, reinitiate at 3 or 10 mg (Lundin 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Solid organ transplantation: </b> Campath:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Heart transplant, induction (off-label use):</b> IV: 30 mg once intra-operatively at the time of transplant followed by minimized maintenance immunosuppression (Teuteberg 2010). Additional data may be necessary to further define the role of alemtuzumab in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lung transplant, induction (off-label use):</b> IV, SubQ: 30 mg once either immediately before allograft reperfusion or immediately following transplant; followed by minimized maintenance immunosuppression (Jaksch 2014; Shyu 2011; Whited 2015). Additional data may be necessary to further define the role of alemtuzumab in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Renal transplant, induction (off-label use):</b> IV: 30 mg as a single dose at the time of transplant (immediately following reperfusion) followed by a second 30 mg dose 24 hours later (the second dose was omitted in patients &gt;60 years of age); followed by minimized maintenance immunosuppression (Haynes 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Renal transplant, steroid resistant cellular rejection (off-label use):</b> IV, SubQ: 15 to 30 mg/dose SubQ on 2 subsequent days (van den Hoogen 2013) <b>or</b> 30 mg/dose IV over 2 to 4 hours for 1 to 2 doses (Basu 2005). Additional data may be necessary to further define the role of alemtuzumab in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Stem cell transplant (allogeneic) conditioning regimen (off-label use):</b> Campath: IV: 20 mg daily for 5 days (in combination with fludarabine and melphalan) beginning 8 days prior to transplant (Mead 2010) <b>or</b> beginning 7 days prior to transplant (Van Besien 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>T-cell large granular lymphocytic leukemia (off-label use):</b> Campath: IV: 10 mg daily for 10 days; patients received a 1 mg test dose initially (Dumitriu 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>T-cell prolymphocytic leukemia (T-PLL; off-label use):</b> Campath: IV: Initial test dose 3 mg or 10 mg, followed by dose escalation to 30 mg per dose 3 times weekly as tolerated until maximum response (Dearden 2001) <b>or</b> Initial dose: 3 mg day 1, if tolerated increase to 10 mg day 2, if tolerated increase to 30 mg on day 3 (days 1, 2, and 3 are consecutive days), followed by 30 mg per dose every Monday, Wednesday, Friday for a total of 4 to 12 weeks (Keating 2002)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50944438\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Aplastic anemia, refractory (off-label use):</b> Campath:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;2 years of age and Adolescents (&lt;50 kg): IV: 0.2 mg/kg/dose (maximum: 10 mg/dose) for 10 days (as monotherapy); patients received a 1 mg test dose initially (Scheinberg 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;2 years of age and Adolescents (&ge;50 kg): IV: 10 mg daily for 10 days (as monotherapy); patients received a 1 mg test dose initially (Scheinberg 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hemophagocytic lymphohistiocytosis, refractory (off-label use): </b>Infants, Children, and Adolescents: Campath: IV, SubQ:<b> Note: </b>The optimal dose and duration of therapy is not known. Median dose: 1 mg/kg (range 0.1 to 8.9 mg/kg; maximum initial dose: 3 mg) <b>divided</b> over a median of 4 days (range 2 to 10 days); refer to article for further information (Marsh 2013)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131180\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671340\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671341\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26340642\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <i>American Society for Blood and Marrow Transplantation (ASBMT) practice guideline committee position statement on chemotherapy dosing in obesity:</i> Utilize a flat dose based on the regimen selected for hematopoietic stem cell transplant conditioning in adults (Bubalo 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131202\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment for nonhematologic toxicity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treatment of B-CLL: Campath, MabCampath [Canadian product]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> If treatment is withheld &ge;7 days, reinitiate at 3 mg with re-escalation to 10 mg and then 30 mg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 3 or 4 infusion reaction: Withhold infusion</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serious infection or other serious adverse reaction: Withhold alemtuzumab until resolution</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Autoimmune anemia or autoimmune thrombocytopenia: Discontinue alemtuzumab</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treatment of MS: Lemtrada: Serious infusion reaction: Consider immediate discontinuation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment for hematologic toxicity (severe neutropenia or thrombocytopenia, not autoimmune):</b> Treatment of B-CLL: Campath, MabCampath [Canadian product]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> If treatment is withheld &ge;7 days, reinitiate at 3 mg with re-escalation to 10 mg and then 30 mg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ANC &lt;250/mm<sup>3</sup> and/or platelet count &le;25,000/mm<sup>3</sup>:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">First occurrence: Withhold treatment; resume at 30 mg per dose when ANC &ge;500/mm<sup>3</sup> and platelet count &ge;50,000/mm<sup>3</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Second occurrence: Withhold treatment; resume at 10 mg per dose when ANC &ge;500/mm<sup>3</sup> and platelet count &ge;50,000/mm<sup>3</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Third occurrence: Discontinue alemtuzumab.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients with a baseline ANC &le;250/mm<sup>3</sup> and/or a baseline platelet count &le;25,000/mm<sup>3</sup> at initiation of therapy: If ANC and/or platelet counts decrease to &le;50% of the baseline value:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">First occurrence: Withhold treatment; resume at 30 mg per dose upon return to baseline values</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Second occurrence: Withhold treatment; resume at 10 mg per dose upon return to baseline values</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Third occurrence: Discontinue alemtuzumab.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26536171\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Campath: 30 mg/mL (1 mL) [contains edetate disodium dihydrate, mouse (murine) and/or hamster protein, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lemtrada: 12 mg/1.2 mL (1.2 mL) [contains edetate disodium dihydrate, mouse (murine) and/or hamster protein, polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131144\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24943496\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">MabCampath: 30 mg/mL (1 mL) [contains edetate disodium, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lemtrada: 10 mg/mL (1.2 mL) [contains edetate disodium, polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14944659\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">As of September 4, 2012, alemtuzumab (Campath) is no longer commercially available in the United States (or Europe); a restricted distribution program will allow access (free of charge) for appropriate patients. Information on necessary documentation and requirements is available at Campath Distribution Program (1-877-422-6728) or Genzyme Medical Information (1-800-745-4447, option 2).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26619137\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103948s5158lbl.pdf#page=22&amp;token=Cr46oBPHQdg2wb6l+0d/lAhJdZxTVxusEp4tOh+QzX1RzCjJZvIEymvcosoie0Xd+iZxWAKqPXcPJv/whPbi/MliALbuWRfY9kDq6YbvD8W6DOnCTCyQAKKA33qA/KkU&amp;TOPIC_ID=8725\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103948s5158lbl.pdf#page=22</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131160\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Campath or MabCampath [Canadian product]: Administer by IV infusion over 2 hours. Premedicate with diphenhydramine 50 mg and acetaminophen 500 to 1000 mg 30 minutes before each infusion. IV glucocorticoids have been effective in decreasing severe infusion-related events. Start anti-infective prophylaxis. Other drugs should not be added to or simultaneously infused through the same IV line. Do not give IV push or bolus. Compatible in polyvinylchloride (PVC) or polyethylene lined administration sets or low protein binding filters. May be given through peripheral IV.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infusion times may have varied in studies for off-label uses; refer to specific reference citations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lemtrada: Administer by IV infusion over 4 hours (beginning within 8 hours after dilution); do not administer by IV push or IV bolus. May extend the infusion duration if clinically indicated. Do not infuse other medications through the same IV line. Premedicate with corticosteroids (methylprednisolone 1,000 mg or equivalent) for first 3 days of each treatment course. Administer in a setting with personnel and equipment appropriate to manage infusion reactions. Monitor vital signs prior to and periodically during the infusion. Infusion reactions should be managed symptomatically; consider discontinuing immediately for severe infusion reaction. Observe for at least 2 hours after each infusion, longer if clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ: Campath: SubQ (off-label route): SubQ administration has been studied (Lundin 2002; Stilgenbauer 2009); an increased rate of injection site reactions has been observed, with only rare incidences of chills or infusion-like reactions typically observed with IV infusion. A longer dose escalation time (1 to 2 weeks) may be needed due to injection site reactions (Lundin 2002). Premedicate with diphenhydramine 50 mg and acetaminophen 500 to 1000 mg 30 minutes before dose. The subQ route should <b>NOT</b> be used for the treatment of T-PLL (Deardon 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alemtuzumab is associated with a moderate emetic potential in adults in the oncology setting; antiemetics may be recommended to prevent nausea and vomiting (Hesketh 2017; Roila 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131159\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>B-cell chronic lymphocytic leukemia:</b> Campath or MabCampath [Canadian product]: Treatment (as a single agent) of B-cell chronic lymphocytic leukemia (B-CLL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple sclerosis, relapsing:</b> Lemtrada: Treatment of patients with relapsing forms of multiple sclerosis (MS), generally reserved for patients who have had an inadequate response to 2 or more medications indicated for the treatment of MS.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475021\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute graft-versus-host disease (steroid refractory) (treatment); Aplastic anemia, refractory; Autoimmune hemolytic anemia, chronic lymphocytic leukemia (CLL)-induced; B-cell chronic lymphocytic leukemia (B-CLL) (subcutaneous [off-label route]); Hemophagocytic lymphohistiocytosis, refractory; Mycosis fungoides/S&eacute;zary syndrome (advanced); Solid organ transplantation: Heart transplant (induction); Solid organ transplantation: Lung transplant (induction); Solid organ transplantation: Renal transplant (induction); Solid organ transplantation: Renal transplant (steroid-resistant cellular rejection); Stem cell transplant (allogeneic) conditioning regimen and/or graft-versus-host disease prophylaxis; T-cell large granular lymphocytic leukemia (TLGLL); T-cell prolymphocytic leukemia (T-PLL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3401548\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Duplicate therapy issues: Campath and MabCampath contain alemtuzumab, which is the same ingredient contained in Lemtrada; patients receiving Lemtrada should not be treated with Campath or MabCampath. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131150\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple sclerosis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Headache (52%), fatigue (18%), insomnia (16%), paresthesia (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dermatologic: Skin rash (53%), urticaria (16%), pruritus (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocrine &amp; metabolic: Thyroid disease (13% to 34%; including Graves disease, hyperthyroidism, hypothyroidism)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Nausea (21%), diarrhea (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Genitourinary: Urinary tract infection (19%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hematologic &amp; oncologic: Lymphocytopenia (100%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immunologic: Antibody development (neutralizing: 5% to 94%; anti-alemtuzumab: 2% to 83%; no effect on drug efficacy)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infection: Infection (71%), herpes virus infection (16%), fungal infection (12% to 13%; including oral candidiasis, vulvovaginal candidiasis)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Local: Infusion-related reaction (92%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neuromuscular &amp; skeletal: Arthralgia (12%), back pain (12%), limb pain (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Respiratory: Nasopharyngitis (25%), upper respiratory tract infection (16%), oropharyngeal pain (11%), sinusitis (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Miscellaneous: Fever (29%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular: Flushing (10%), tachycardia (8%), chest discomfort (7%), peripheral edema (5%), atrial fibrillation (&le;3%), bradycardia (&le;3%), chest pain (&le;3%), hypertension (&le;3%), hypotension (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Dizziness (10%), chills (9%), anxiety (7%), neurological signs and symptoms (&le;3%; transient)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dermatologic: Dermatitis (8%), erythema (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Abdominal pain (10%), vomiting (10%), oral herpes (9%), dysgeusia (8%), dyspepsia (8%), appendicitis (&le;3%), gastroenteritis (&le;3%), tooth infection (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Genitourinary: Occult blood in urine (8%), uterine hemorrhage (5%), herpes genitalis (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hematologic &amp; oncologic: Decreased CD-4 cell count (6%), decreased CD-8 cell counts (6%), decreased T cell lymphocytes (5%), immune thrombocytopenia (2%), hematoma (1%), petechia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hypersensitivity: Angioedema (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infection: Influenza (8%), herpes zoster (4%), herpes simplex infection (2%), human papilloma virus infection (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neuromuscular &amp; skeletal: Myasthenia (7%), muscle spasm (6%), myalgia (6%), neck pain (5%), weakness (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ophthalmic: Graves ophthalmopathy (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Respiratory: Cough (9%), dyspnea (8%), bronchitis (7%), epistaxis (5%), bronchospasm (&le;3%), pneumonia (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Pain</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Respiratory: Hypersensitivity pneumonitis, pneumonitis (with fibrosis), pulmonary infiltrates</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>B-cell chronic lymphocytic leukemia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular: Hypotension (16%), cardiac arrhythmia (14%), hypertension (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Chills (53%), headache (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dermatologic: Urticaria (16%), skin rash (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hematologic &amp; oncologic: Lymphocytopenia (97%; grades 3/4: 97%), neutropenia (77%; grades 3/4: 42% to 64%), anemia (76%; grades 3/4: 12% to 38%), thrombocytopenia (71%; grades 3/4: 13% to 52%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infection: Infection (50% to 74%), CMV viremia (55%), cytomegalovirus disease (6% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Respiratory: Dyspnea (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Miscellaneous: Fever (69%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular: Tachycardia (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Insomnia (10%), anxiety (8%), dysesthesia (&gt;5%), fatigue (&gt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dermatologic: Erythema (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Diarrhea (10%), anorexia (&gt;5%), mucositis (&gt;5%), nausea (&gt;5%), vomiting (&gt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hematologic &amp; oncologic: Febrile neutropenia (&ge; grade 3: 5% to 10%), autoimmune thrombocytopenia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immunologic: Antibody development (2% to 8%; neutralizing: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infection: Sepsis (&ge; grade 3: 3% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neuromuscular &amp; skeletal: Musculoskeletal pain (&gt;5%), tremor (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Respiratory: Bronchospasm (&gt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports (any indication): Anaphylactic shock, anaphylaxis, anemia, anti-GBM disease, aplastic anemia, autoimmune hemolytic anemia, bone marrow aplasia, bone marrow depression, bone marrow hypoplasia, cardiac failure, cardiomyopathy, cholecystitis, chronic inflammatory demyelinating polyradiculoneuropathy, connective tissue disease (undifferentiated), Epstein-Barr-associated lymphoproliferative disorder, Epstein-Barr infection, Goodpasture syndrome, graft versus host disease (transfusion associated), Graves disease, Guillain-Barre syndrome, hemolytic anemia, hemophilia A (acquired [anti-Factor VIII antibodies]), listeriosis (including encephalitis, sepsis), lymphoproliferative disorder, malignant lymphoma, malignant melanoma, malignant neoplasm of thyroid, membranous glomerulonephritis, meningitis due to listeria monocytogenes, meningitis (herpes), neutropenia, optic neuropathy, pancytopenia, pneumonitis, progressive multifocal leukoencephalopathy, pure red cell aplasia, reactivation of disease, reduced ejection fraction, retinal pigment changes (epitheliopathy), rheumatoid arthritis, serum sickness, suicidal ideation, suicidal tendencies, syncope, tuberculosis, tumor lysis syndrome, type 1 diabetes mellitus, vitiligo</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131163\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i> Lemtrada is contraindicated in patients infected with HIV (due to prolonged reduction in CD4+ lymphocytes). There are no contraindications listed in the manufacturer's Campath labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lemtrada: Hypersensitivity to alemtuzumab or any component of the formulation; HIV infection; active or latent tuberculosis; severe active infections; active malignancies; concurrent antineoplastic or immunosuppressive therapy; history of progressive multifocal leukoencephalopathy (PML)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">MabCampath: Known type 1 hypersensitivity or anaphylactic reactions to alemtuzumab or any component of the formulation; active infections; underlying immunodeficiency (eg, seropositive for HIV); active secondary malignancies; current or history of progressive multifocal leukoencephalopathy (PML)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131148\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autoimmune effects: <b>[US Boxed Warning (Lemtrada)]: Alemtuzumab causes serious, sometimes fatal, autoimmune conditions, such as immune thrombocytopenia and antiglomerular basement membrane disease, in patients receiving alemtuzumab for the treatment of multiple sclerosis (MS). Monitor complete blood counts with differential, serum creatinine levels, and urinalysis with urine cell counts at periodic intervals for 48 months after the last dose of alemtuzumab.</b> Monitor for symptoms of immune thrombocytopenia (easy bruising, petechiae, spontaneous mucocutaneous bleeding, heavy menstrual bleeding) in patients receiving alemtuzumab for MS. Monitor for nephropathy symptoms (eg, elevated serum creatinine, hematuria, proteinuria). Alveolar hemorrhage manifesting as hemoptysis may be present in antiglomerular basement membrane disease. Glomerular nephropathies require urgent evaluation; may lead to renal failure if not treated. Prompt intervention is necessary for autoimmune cytopenias. Immune thrombocytopenia (formerly known as idiopathic thrombocytopenic purpura), thyroid disorders, autoimmune hemolytic anemia, autoimmune pancytopenia, undifferentiated connective tissue disorders, acquired hemophilia A, rheumatoid arthritis, type 1 diabetes, vitiligo, and retinal pigment epitheliopathy have been reported in patients receiving alemtuzumab for MS. Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy have been reported in patients receiving alemtuzumab for other uses. Alemtuzumab may increase the risk for other autoimmune conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: <b>[US Boxed Warning (Campath)]: Serious and fatal cytopenias (including pancytopenia, bone marrow hypoplasia, autoimmune hemolytic anemia, and autoimmune idiopathic thrombocytopenia) have occurred. Single doses &gt;30 mg or cumulative weekly doses &gt;90 mg are associated with an increased incidence of pancytopenia.</b> Severe prolonged myelosuppression, hemolytic anemia, pure red cell aplasia, bone marrow aplasia, and bone marrow hypoplasia have also been reported with use at the normal dose for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). Discontinue for serious hematologic or other serious toxicity (except lymphopenia) until the event resolves. Permanently discontinue if autoimmune anemia or autoimmune thrombocytopenia occurs. Patients receiving blood products should only receive irradiated blood products due to the potential for transfusion-associated graft-versus-host disease (GVHD) during lymphopenia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cholecystitis: In a clinical trial of MS patients, an increased risk of acute acalculous cholecystitis was observed in patients receiving alemtuzumab versus interferon beta-1a; additional postmarketing cases have also been reported. Symptom onset ranged from &lt;24 hours to 2 months after alemtuzumab infusion. Some patients recovered without surgical intervention (and received antibiotics); some patients underwent cholecystectomy. Monitor closely (acute acalculous cholecystitis is associated with high morbidity and mortality); symptoms may include abdominal pain/tenderness, fever, nausea, vomiting, leukocytosis, and abnormal liver enzymes. Evaluate and treat promptly if acute acalculous cholecystitis is suspected or diagnosed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI toxicity: Alemtuzumab is associated with a moderate emetic potential in adults in the oncology setting; antiemetics may be recommended to prevent nausea and vomiting (Hesketh 2017; Roila 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: <b>[US Boxed Warning (Campath)]: Serious and potentially fatal infections (bacterial, viral, fungal, and protozoan) have been reported. Administer prophylactic medications against PCP pneumonia and herpes viral infections during treatment</b> and for at least 2 months following last dose or until CD4<sup>+</sup> counts are &ge;200 cells/mm<sup>3</sup> (whichever is later). Severe and prolonged lymphopenia may occur; CD4<sup>+</sup> counts usually return to &ge;200 cells/mm<sup>3</sup> within 2 to 6 months; however, CD4<sup>+</sup> and CD8<sup>+</sup> lymphocyte counts may not return to baseline levels for more than 1 year. Withhold treatment during serious infections; may be reinitiated upon resolution of infection. Monitor for cytomegalovirus (CMV) infection (during and for at least 2 months after completion of therapy); initiate appropriate antiviral treatment and withhold alemtuzumab for CMV infection or confirmed CMV viremia (withhold alemtuzumab during CMV antiviral treatment). For patients being treated for MS, initiate antiviral prophylaxis (for herpetic viral infections) beginning on the first day of treatment and continue for at least 2 months or until CD4<sup>+</sup> lymphocyte count is &ge;200/mm<sup>3</sup>. In clinical trials for MS, infections seen more commonly in alemtuzumab-treated patients included nasopharyngitis, urinary tract infection, upper respiratory tract infection, sinusitis, herpetic infections, influenza, and bronchitis; serious cases of appendicitis, gastroenteritis, pneumonia, herpes zoster, and tooth infection also occurred. <i>Listeria monocytogenes </i>infections (encephalitis, gastroenteritis, meningitis, sepsis), including fatal cases of <i>Listeria </i>meningoencephalitis have been reported; <i>Listeria </i>infections have developed as early as 3 days post treatment and up to 8 months after the last dose for MS. Patients should avoid or adequately heat foods that may potentially carry this bacteria (eg, deli meat, dairy products made with unpasteurized milk, soft cheeses, or undercooked meat, seafood, or poultry). The incubation period for <i>Listeria monocytogenes </i>ranges from 3 to 70 days; signs/symptoms of invasive listeriosis generally start within 1 month of exposure. Symptoms of <i>Listeria </i>infection include fever, chills, diarrhea, nausea, vomiting, headache, pains in joints and muscles, neck stiffness, difficulty walking, mental status changes, coma, and other neurologic changes. Treatment (eg, with anti-infectives) may not adequately prevent <i>Listeria</i> infection-related morbidity/mortality. Consider delaying treatment in patients with any active infection until infection is controlled. Screen for tuberculosis (per local guidelines). Patients should be screened for human papilloma virus (HPV) as clinically necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: <b>[US Boxed Warning]: Serious and potentially fatal infusion-related reactions may occur; monitor for infusion reaction; carefully monitor during infusion; withhold treatment for serious or grade 3 or 4 infusion reactions. For B-CLL, gradual escalation to the recommended maintenance dose is required at initiation and with treatment interruptions (for &ge;7 days) to minimize infusion-related reactions. For MS, must be administered in a setting with appropriate equipment and personnel to manage anaphylaxis or serious infusion reaction; monitor for 2 hours after each infusion; inform patients that serious infusion reactions may also occur after the 2-hour monitoring period.</b> Infusion reactions have been reported more than 24 hours after infusion. In patients treated for B-CLL, infusion reaction symptoms may include acute respiratory distress syndrome, anaphylactic/anaphylactoid shock, angioedema, bronchospasm, cardiac arrest, cardiac arrhythmias, chills, dyspnea, fever, hypotension, myocardial infarction, pulmonary infiltrates, rash, rigors, syncope, or urticaria. The incidence of infusion reaction is highest during the first week of B-CLL treatment. Premedicate with acetaminophen and an oral antihistamine. Medications for the treatment of reactions should be available for immediate use. Use caution and carefully monitor blood pressure in patients with ischemic heart disease and patients on antihypertensive therapy. For B-CLL, reinitiate with gradual dose escalation if treatment is withheld &ge;7 days. Similar infusion reactions have been observed with use in the treatment of multiple sclerosis; premedication with corticosteroids for initial 3 days of each treatment course is recommended. Antihistamines and/or antipyretics may also be considered. Consider additional monitoring in patients with existing cardiovascular or respiratory compromise. Observe for infusion-related reactions; advise patients to monitor for signs/symptoms of infusion reaction, particularly during the 24 hours following infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: <b>[US Boxed Warning (Lemtrada)]: Alemtuzumab may cause an increased risk of malignancies, including thyroid cancer, melanoma, and lymphoproliferative disorders. Perform baseline and yearly skin exams.</b> Other malignant neoplasm (breast cancer or basal cell carcinoma) has been observed (rarely) in patients receiving treatment for MS. Use caution if initiating treatment in patients with preexisting or ongoing malignancies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pneumonitis: Pneumonitis (hypersensitivity or fibrosis) has been reported. Monitor for symptoms (dyspnea, cough, wheezing, hemoptysis, chest pain/tightness).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Progressive multifocal leukoencephalopathy (PML): Has been reported with use (rarely); withhold therapy immediately for signs/symptoms suggestive of PML.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disorders: Autoimmune thyroid disorders occurred in over one-third of patients receiving alemtuzumab for MS. In a trial evaluating alemtuzumab versus interferon beta-1a in patients with MS, thyroid dysfunction occurred more frequently in patients taking alemtuzumab (34% versus 6.5%) (Daniels 2014). The incidence of the first episode of thyroid dysfunction increased annually the first 3 years (year 1: 4.6%; year 2: 13.3%; year 3: 16.1%) then gradually decreased thereafter. Among patients with alemtuzumab-related thyroid dysfunction, Graves hyperthyroidism occurred most commonly (23%), followed by hypothyroidism and subacute thyroiditis (7% and 4%, respectively). Thyroid dysfunction (thyroiditis, Graves disease) has also been reported with alemtuzumab use for the treatment of other conditions. For B-CLL treatment, thyroid-stimulating hormone (TSH) monitoring is recommended; monitor TSH at baseline and every 2 to 3 months during alemtuzumab treatment (Hamnvik 2011). For MS, monitor TSH at baseline and every 3 months until 48 months after last infusion or longer or at any time during therapy if clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; HBV or HCV infected patients: Alemtuzumab has not been studied in MS patients infected with HBV or HCV; consider screening patients at increased risk of infection prior to initiating treatment. Use with caution in HBV or HCV carriers; patients may be at risk for viral reactivation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Alemtuzumab is not recommended for use in MS patients with inactive disease or who are stable on other treatment. Patients should commit to at least 48 months of follow-up after the last infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Duplicate therapy: If considering Lemtrada treatment for use in a patient who has previously received Campath/MabCampath, consider the additive and long-lasting immune system effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Patients should not be immunized with live, viral vaccines during or recently after treatment. The ability to respond to any vaccine following therapy is unknown. Testing for antibodies to varicella zoster virus (VZV) is recommended prior to initiation of Lemtrada if history of chickenpox or VZV vaccination status is unknown. When using for the treatment of MS, complete necessary immunizations at least 6 weeks prior to initiating alemtuzumab. Determine if patient has a history varicella or vaccination for VZV; if not, test for VZV antibodies and consider vaccinations for antibody-negative patients; postpone alemtuzumab treatment for 6 weeks following VZV vaccination.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; REMS Program: <b>[US Boxed Warning (Lemtrada)]: Due to the risk of autoimmunity, infusion reactions, and malignancies, alemtuzumab is available only through restricted distribution under a Risk Evaluation Mitigation Strategy (REMS) Program when used for the treatment of MS. Contact 1-855-676-6326 to enroll in the Lemtrada REMS program.</b> Prescribers and pharmacies must be certified with the REMS program, and patients and healthcare facilities must be enrolled and comply with ongoing monitoring.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298700\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2139162\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8725&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131154\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131165\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Human IgG is known to cross the placental barrier; therefore, alemtuzumab may also cross the barrier and cause fetal B- and T-lymphocyte depletion. Use during pregnancy only if the benefit to the mother outweighs the potential risk to the fetus. Effective contraception is recommended during and for at least 6 months (Campath) after treatment for women and men of reproductive potential or 4 months (Lemtrada) after a treatment course for women of reproductive potential.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131166\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Human IgG is present in breast milk; therefore, alemtuzumab may also be present in milk. Due to the potential for serious adverse reactions in the breastfed infant, the decision to discontinue alemtuzumab or to discontinue breastfeeding should take into account the importance of treatment to the mother and the half-life of alemtuzumab. The Canadian labeling recommends discontinuing breastfeeding during treatment and for at least 3 months (MabCampath) or 4 months (Lemtrada) after completing treatment course.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131156\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Campath: CBC with differential and platelets (weekly, more frequent if worsening); signs and symptoms of infection; CD4<sup>+</sup> lymphocyte counts (after treatment until recovery); CMV antigen (routinely during and for 2 months after treatment); consider TSH at baseline and then every 2 to 3 months during alemtuzumab treatment (Hamnvik 2011). Monitor closely for infusion reactions (including hypotension, rigors, fever, shortness of breath, bronchospasm, chills, and/or rash); vital signs (prior to and during infusion); carefully monitor BP especially in patients with ischemic heart disease or on antihypertensive medications.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Lemtrada: CBC with differential prior to initiation then monthly until 48 months after last infusion; serum creatinine prior to initiation then monthly until 48 months after last infusion or at any time during therapy if clinically indicated; urinalysis with urine cell counts (prior to initiation then monthly); signs/symptoms of infection; TSH at baseline and every 3 months until 48 months after last infusion or longer or at any time during therapy if clinically indicated; observe for at least 2 hours after each infusion, longer if clinically indicated; ECG prior to each treatment course; annual HPV screening; tuberculosis screening; signs/symptoms of PML; baseline and annual skin exams (for melanoma).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131147\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Alemtuzumab binds to CD52, a nonmodulating antigen present on the surface of B and T lymphocytes, a majority of monocytes, macrophages, NK cells, and a subpopulation of granulocytes. After binding to CD52<sup>+</sup> cells, an antibody-dependent lysis of malignant cells occurs. In multiple sclerosis, alemtuzumab immunomodulatory effects may include alteration in the number, proportions, and properties of some lymphocyte subsets following treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131162\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: IV: Campath: 0.18 L/kg (range: 0.1 to 0.4 L/kg); Lemtrada: 14.1 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Campath: Clearance decreases with repeated dosing (due to loss of CD52 receptors in periphery), resulting in a sevenfold increase in AUC after 12 weeks of therapy. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IV: Campath: 11 hours (following first 30 mg dose; range: 2 to 32 hours); 6 days (following the last 30 mg dose; range: 1 to 14 days); Lemtrada: ~2 weeks</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26597090\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Campath Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg/mL (1 mL): $0.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Lemtrada Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12 mg/1.2 mL (1.2 mL): $26,160.38</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131167\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Campath (PE, UY);</li>\n      <li>Lemtrada (AT, AU, CZ, DE, DK, EE, GB, HK, HR, HU, IE, KR, LT, LU, LV, MT, MY, NL, PL, RO, SE, SG, SI);</li>\n      <li>Lemttrada (NO);</li>\n      <li>MabCampath (AU, CY, FR, GB, HN, HU, ID, IL, JP, KR, LI, MY, NO, RU, SE, SG, SI, SK, TH, TR, ZA);</li>\n      <li>Mabcampath (JO);</li>\n      <li>Remniq (AU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15848576\"></a>Basu A, Ramkumar M, Tan HP, et al, &ldquo;Reversal of Acute Cellular Rejection After Renal Transplantation With Campath-1H,&rdquo; <i>Transplant Proc</i>, 2005, 37(2):923-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/15848576/pubmed\" target=\"_blank\" id=\"15848576\">15848576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berger JR and Houff S, &ldquo;Opportunistic Infections and Other Risks With Newer Multiple Sclerosis Therapies,&rdquo; <i>Ann Neurol</i>, 2009, 65(4):367-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/19399841/pubmed\" target=\"_blank\" id=\"19399841\">19399841</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bubalo J, Carpenter PA, Majhail N, et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. <i>Biol Blood Marrow Transplant</i>. 2014;20(5):600-616.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/24462742/pubmed\" target=\"_blank\" id=\"24462742\">24462742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    CAMMS223 Trial Investigators: Coles AJ, Compston DA, Selmaj KW, et al, &ldquo;Alemtuzumab vs Interferon Beta-1a in Early Multiple Sclerosis,&rdquo; <i>N Engl J Med</i>, 2008, 359(17):1786-801.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/18946064/pubmed\" target=\"_blank\" id=\"18946064\">18946064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Campath (alemtuzumab) [prescribing information]. Cambridge, MA: Genzyme Corporation; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ciancio G, Burke GW, Gaynor JJ, et al, &ldquo;A Randomized Trial of Three Renal Transplant Induction Antibodies: Early Comparison of Tacrolimus, Mycophenolate Mofetil, and Steroid Dosing, and Newer Immune-Monitoring,&rdquo; <i>Transplantation</i>, 2005, 80(4):457-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/16123718/pubmed\" target=\"_blank\" id=\"16123718\">16123718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coles AJ, Fox E, Vladic A, et al, &ldquo;Alemtuzumab More Effective Than Interferon &Beta;-1a at 5-Year Follow-Up of CAMMS223 Clinical Trial,&rdquo; Neurology, 2012, 78(14):1069-78.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/22442431/pubmed\" target=\"_blank\" id=\"22442431\">22442431</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cuker A, Coles AJ, Sullivan H, et al, &ldquo;A Distinctive Form of Immune Thrombocytopenia in a Phase 2 Study of Alemtuzumab for the Treatment of Relapsing-Remitting Multiple Sclerosis,&rdquo; <i>Blood</i>, 2011, 118(24):6299-305.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/21960587/pubmed\" target=\"_blank\" id=\"21960587\">21960587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daniels GH, Vladic A, Brinar V, et al. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. <i>J Clin Endocrinol Metab</i>. 2014;99(1):80-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/24170099/pubmed\" target=\"_blank\" id=\"24170099\">24170099</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21480860\"></a>Dearden CE, Johnson R, Pettengell R, et al, &ldquo;Guidelines for the Management of Mature T-Cell and NK-Cell Neoplasms (Excluding Cutaneous T-Cell Lymphoma),&rdquo; <i>Br J Haematol</i>, 2011, 153(4):451-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/21480860/pubmed\" target=\"_blank\" id=\"21480860\">21480860</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dearden CE, Matutes E, Cazin B, et al, &ldquo;High Remission Rate in T-Cell Prolymphocytic Leukemia With CAMPATH-1H,&rdquo; <i>Blood</i>, 2001, 98(6):1721-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/11535503/pubmed\" target=\"_blank\" id=\"11535503\">11535503</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26765645\"></a>Dumitriu B, Ito S, Feng X, et al. Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study. <i>Lancet Haematol.</i> 2016;3(1):e22-e29.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/26765645/pubmed\" target=\"_blank\" id=\"26765645\">26765645</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/23512831/pubmed\" target=\"_blank\" id=\"23512831\">23512831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Enblad G, Hagberg H, Erlanson M, et al, &ldquo;A Pilot Study of Alemtuzumab (Anti-CD52 Monoclonal Antibody) Therapy for Patients With Relapsed or Chemotherapy-Refractory Peripheral T-cell Lymphomas,&rdquo; <i>Blood</i>, 2003, 103(8):2920-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/15070664/pubmed\" target=\"_blank\" id=\"15070664\">15070664</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farney A, Sundberg A, Moore P, et al, &ldquo;A Randomized Trial of Alemtuzumab vs Anti-Thymocyte Globulin Induction in Renal and Pancreas Transplantation,&rdquo; <i>Clin Transplant</i>, 2008, 22(1):41-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/18217904/pubmed\" target=\"_blank\" id=\"18217904\">18217904</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferrajoli A, O'Brien SM, Cortes JE, et al, &ldquo;Phase II Study of Alemtuzumab in Chronic Lymphoproliferative Disorders,&rdquo; <i>Cancer</i>, 2003, 98(4):773-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/12910522/pubmed\" target=\"_blank\" id=\"12910522\">12910522</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26833657\"></a>Furuya Y, Jayarajan SN, Taghavi S, et al. The impact of alemtuzumab and basiliximab induction on patient survival and time to bronchiolitis obliterans syndrome in double lung transplantation recipients. <i>Am J Transplant</i>. 2016;16(8):2334-2341.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/26833657/pubmed\" target=\"_blank\" id=\"26833657\">26833657</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hale G, Rebello P, Brettman LR, et al, &ldquo;Blood Concentrations of Alemtuzumab and Antiglobulin Responses in Patients With Chronic Lymphocytic Leukemia Following Intravenous or Subcutaneous Routes of Administration, <i>Blood</i>, 2004, 104(4):948-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/15090452/pubmed\" target=\"_blank\" id=\"15090452\">15090452</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hamnvik OP, Larsen PR, and Marqusee E, &ldquo;Thyroid Dysfunction From Antineoplastic Agents,&rdquo; <i>J Natl Cancer Inst</i>, 2011, 103(21):1572-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/22010182/pubmed\" target=\"_blank\" id=\"22010182\">22010182</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21591943\"></a>Hanaway MJ, Woodle ES, Mulgaonkar S, et al, &ldquo;Alemtuzumab Induction In Renal Transplantation,&rdquo; <i>N Engl J Med</i>, 2011, 364(20):1909-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/21591943/pubmed\" target=\"_blank\" id=\"21591943\">21591943</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25078310\"></a>Haynes R, Harden P, Judge P, et al. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. <i>Lancet</i>. 2014;384(9955):1684-1690.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/25078310/pubmed\" target=\"_blank\" id=\"25078310\">25078310</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28759346\"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2017;35(28):3240-3261. doi: 10.1200/JCO.2017.74.4789.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/28759346/pubmed\" target=\"_blank\" id=\"28759346\">28759346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hillmen P, Skotnicki A, Robak T, et al, &ldquo;Alemtuzumab Compared With Chlorambucil as First-Line Therapy for Chronic Lymphocytic Leukemia,&rdquo; <i>J Clin Oncol</i>, 2007, 25(35):5616-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/17984186/pubmed\" target=\"_blank\" id=\"17984186\">17984186</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25039364\"></a>Jaksch P, Ankersmit J, Scheed A, et al. Alemtuzumab in lung transplantation: an open-label, randomized, prospective single center study. <i>Am J Transplant</i>. 2014;14(8):1839-1845.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/25039364/pubmed\" target=\"_blank\" id=\"25039364\">25039364</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kanda J, Lopez RD, and Rizzieri DA, &quot;Alemtuzumab for the Prevention and Treatment of Graft-Versus-Host Disease,&quot; <i>Int J Hematol</i>, 2011, 93(5):586-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/21369856/pubmed\" target=\"_blank\" id=\"21369856\">21369856</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17215854\"></a>Karlsson C, Hansson L, Celsing F, et al, &ldquo;Treatment of Severe Refractory Autoimmune Hemolytic Anemia in B-Cell Chronic Lymphocytic Leukemia With Alemtuzumab (Humanized CD52 Monoclonal Antibody),&rdquo; <i>Leukemia</i>, 2007, 21(3):511-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/17215854/pubmed\" target=\"_blank\" id=\"17215854\">17215854</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keating MJ, Cazin B, Coutr&eacute; S, et al, &ldquo;Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed,&rdquo; <i>J Clin Oncol</i>, 2002, 20(1):205-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/11773171/pubmed\" target=\"_blank\" id=\"11773171\">11773171</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11986207\"></a>Keating MJ, Flinn I, Jain V, et al, &ldquo;Therapeutic Role of Alemtuzumab (Campath-1H) in Patients Who Have Failed Fludarabine: Results of a Large International Study,&rdquo; <i>Blood</i>, 2002, 99(10):3554-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/11986207/pubmed\" target=\"_blank\" id=\"11986207\">11986207</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kennedy B and Hillmen P, &ldquo;Immunological Effects and Safe Administration of Alemtuzumab (MabCampath) in Advanced B-cLL,&rdquo; <i>Med Oncol</i>, 2002, 19(Suppl):49-55.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lemtrada (alemtuzumab) [prescribing information]. Cambridge, MA: Genzyme Corporation; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lemtrada (alemtuzumab) [product monograph]. Mississauga, Ontario, Canada: Genzyme Canada; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lepretre S, Aurran T, Mah&eacute; B, et al, &ldquo;Excess Mortality After Treatment With Fludarabine and Cyclophosphamide in Combination With Alemtuzumab in Previously Untreated Patients With Chronic Lymphocytic Leukemia in a Randomized Phase 3 Trial,&quot; <i>Blood</i>, 2012, 119(22):5104-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/22337714/pubmed\" target=\"_blank\" id=\"22337714\">22337714</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12543862\"></a>Lundin J, Hagberg H, Repp R, et al, &ldquo;Phase 2 Study of Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients With Advanced Mycosis Fungoides/S&eacute;zary Syndrome,&rdquo; <i>Blood</i>, 2003, 101(11):4267-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/12543862/pubmed\" target=\"_blank\" id=\"12543862\">12543862</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12130484\"></a>Lundin J, Kimby E, Bjorkholm M, et al, &ldquo;Phase II Trial of Subcutaneous Anti-CD52 Monoclonal Antibody Alemtuzumab (Campath-1H) as First-Line Treatment for Patients With B-Cell Chronic Lymphocytic Leukemia (B-CLL),&rdquo; <i>Blood</i>, 2002, 100(3):768-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/12130484/pubmed\" target=\"_blank\" id=\"12130484\">12130484</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lundin J, Osterborg A, Brittinger G, et al, &ldquo;CAMPATH-1H Monoclonal Antibody in Therapy for Previously Treated Low-Grade Non-Hodgkin's Lymphomas: A Phase II Multicenter Study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma,&rdquo; <i>J Clin Oncol</i>, 1998, 16(10):3257-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/9779699/pubmed\" target=\"_blank\" id=\"9779699\">9779699</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MabCampath (alemtuzumab) [product monograph]. Mississauga, Ontario, Canada: Genzyme Canada; March 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Magliocca JF and Knechtle SJ, &ldquo;The Evolving Role of Alemtuzumab (Campath-1H) for Immunosuppressive Therapy in Organ Transplantation,&rdquo; <i>Transpl Int</i>, 2006, 19(9):705-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/16918530/pubmed\" target=\"_blank\" id=\"16918530\">16918530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marcos A, Eghtesad B, Fung JJ, et al, &ldquo;Use of Alemtuzumab and Tacrolimus Monotherapy for Cadaveric Liver Transplantation: With Particular Reference to Hepatitis C Virus,&rdquo; <i>Transplantation</i>, 2004, 78(7):966-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/15480160/pubmed\" target=\"_blank\" id=\"15480160\">15480160</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Margreiter R, Klempnauer J, Neuhaus P, et al, &ldquo;Alemtuzumab (Campath-1H) and Tacrolimus Monotherapy After Renal Transplantation: Results of a Prospective Randomized Trial,&rdquo; <i>Am J Transplant</i>, 2008, 8(7):1480-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/18510632/pubmed\" target=\"_blank\" id=\"18510632\">18510632</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22522603\"></a>Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. <i>Pediatr Blood Cancer</i>. 2013;60(1):101-109.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/22522603/pubmed\" target=\"_blank\" id=\"22522603\">22522603</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19361757\"></a>Martinez C, Solano C, Ferr&aacute; C, et al, &ldquo;Alemtuzumab as Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease: Results From a Phase II Study,&rdquo; <i>Biol Blood Marrow Transplant</i>, 2009, 15(5):639-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/19361757/pubmed\" target=\"_blank\" id=\"19361757\">19361757</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20371745\"></a>Mead AJ, Thomson KJ, Morris EC, et al, &ldquo;HLA-Mismatched Unrelated Donors are a Viable Alternate Graft Source for Allogeneic Transplantation Following Alemtuzumab-Based Reduced-Intensity Conditioning,&rdquo; <i>Blood</i>, 2010, 115(25):5147-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/20371745/pubmed\" target=\"_blank\" id=\"20371745\">20371745</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osterborg A, Dyer MJ, Bunjes D, et al, &ldquo;Phase II Multicenter Study of Human CD52 Antibody in Previously Treated Chronic Lymphocytic Leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia,&rdquo; <i>J Clin Oncol</i>, 1997, 15(4):1567-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/9193354/pubmed\" target=\"_blank\" id=\"9193354\">9193354</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osterborg A, Fassas AS, Anagnostopoulos A, et al, &ldquo;Humanifed CD52 Monoclonal Antibody Campath-1H as First-Line Treatment in Chronic Lymphocytic Leukaemia,&rdquo; <i>Br J Haematol</i>, 1996, 93(1):151-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/8611450/pubmed\" target=\"_blank\" id=\"8611450\">8611450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20425438\"></a>Osterborg A, Karlsson C, and Lundin J, &ldquo;Alemtuzumab to Treat Refractory Autoimmune Hemolytic Anemia or Thrombocytopenia in Chronic Lymphocytic Leukemia,&rdquo; <i>Curr Hematol Malig Rep</i>, 2009, 4(1):47-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/20425438/pubmed\" target=\"_blank\" id=\"20425438\">20425438</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pawson R, Dyer MJ, Barge R, et al, &ldquo;Treatment of T-Cell Prolymphocytic Leukemia With Human CD52 Antibody,&rdquo; <i>J Clin Oncol</i>, 1997, 15(7):2667-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/9215839/pubmed\" target=\"_blank\" id=\"9215839\">9215839</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rai KR, Freter CE, Mercier RJ, et al, &ldquo;Alemtuzumab in Previously Treated Chronic Lymphocytic Leukemia Patients Who Also Had Received Fludarabine,&rdquo; <i>J Clin Oncol</i>, 2002, 20(18):3891-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/12228210/pubmed\" target=\"_blank\" id=\"12228210\">12228210</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19995389\"></a>Risitano AM, Selleri C, Serio B, et al; Working Party Severe Aplastic Anaemia (WPSAA) of the European Group for Blood and Marrow Transplantation (EBMT). Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. <i>Br J Haematol.</i> 2010;148(5):791-796.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/19995389/pubmed\" target=\"_blank\" id=\"19995389\">19995389</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015.. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/27664248/pubmed\" target=\"_blank\" id=\"27664248\">27664248</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22067384\"></a>Scheinberg P, Nunez O, Weinstein B, et al, &ldquo;Activity of Alemtuzumab Monotherapy in Treatment-Naive, Relapsed, and Refractory Severe Acquired Aplastic Anemia,&rdquo; <i>Blood</i>, 2012, 119(2):345-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/22067384/pubmed\" target=\"_blank\" id=\"22067384\">22067384</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19589480\"></a>Schnitzler M, Hasskerl J, Egger M, et al, &ldquo;Successful Treatment of Severe Acute Intestinal Graft-Versus-Host Resistant to Systemic and Topical Steroids With Alemtuzumab,&rdquo; <i>Biol Blood Marrow Transplant</i>, 2009, 15(8):910-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/19589480/pubmed\" target=\"_blank\" id=\"19589480\">19589480</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schweighofer CD, Ritgen M, Eichhorst BF, et al, &ldquo;Consolidation With Alemtuzumab Improves Progression-Free Survival in Patients With Chronic Lymphocytic Leukaemia (CLL) in First Remission: Long-Term Follow-Up of a Randomized Phase III Trial of the German CLL Study Group (GCLLSG),&rdquo; <i>Br J Haematol</i>, 2009, 144(1):95-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/19016732/pubmed\" target=\"_blank\" id=\"19016732\">19016732</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21420318\"></a>Shyu S, Dew MA, Pilewski JM, et al. Five-year outcomes with alemtuzumab induction after lung transplantation. <i>J Heart Lung Transplant</i>. 2011;30(7):743-754.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/21420318/pubmed\" target=\"_blank\" id=\"21420318\">21420318</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19597025\"></a>Stilgenbauer S, Zenz T, Winkler D, et al, &ldquo;Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses from the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group,&rdquo; <i>J Clin Oncol</i>, 2009, 27(24):3994-4001.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/19597025/pubmed\" target=\"_blank\" id=\"19597025\">19597025</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19889126\"></a>Teuteberg JJ, Shullo MA, Zomak R, et al. Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. <i>Am J Transplant</i>. 2010;10(2):382-388.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/19889126/pubmed\" target=\"_blank\" id=\"19889126\">19889126</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Treon SP, Soumerai JD, Hunter ZR, et al, &ldquo;Long-Term Follow-Up of Symptomatic Patients With Lymphoplasmacytic Lymphoma/Waldenstr&ouml;m Macroglobulinemia Treated With the Anti-CD52 Monoclonal Antibody Alemtuzumab,&rdquo; <i>Blood</i>, 2011, 118(2):276-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/21566092/pubmed\" target=\"_blank\" id=\"21566092\">21566092</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van Besien K, Artz A, Smith S, et al, &ldquo;Fludarabine, Melphalan, and Alemtuzumab Conditioning in Adults With Standard-Risk Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome,&rdquo; <i>J Clin Oncol</i>, 2005, 23(24):5728-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/16009946/pubmed\" target=\"_blank\" id=\"16009946\">16009946</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19361753\"></a>van Besien K, Kunavakkam R, Rondon G, et al, &ldquo;Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD Without Affecting Long-term Outcomes,&rdquo; <i>Biol Blood Marrow Transplant</i>, 2009, 15(5):610-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/19361753/pubmed\" target=\"_blank\" id=\"19361753\">19361753</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23167538\"></a>van den Hoogen MW, Hesselink DA, van Son WJ, Weimar W, Hilbrands LB. Treatment of steroid-resistant acute renal allograft rejection with alemtuzumab. <i>Am J Transplant.</i> 2013;13(1):192-196. doi: 10.1111/j.1600-6143.2012.04328.x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/23167538/pubmed\" target=\"_blank\" id=\"23167538\">23167538</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vo AA, Wechsler EA, Wang J, et al, &ldquo;Analysis of Subcutaneous (SQ) Alemtuzumab Induction Therapy in Highly Sensitized Patients Desensitized With IVIG and Rituximab,&rdquo; <i>Am J Transplant</i>, 2008, 8(1):144-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/17973966/pubmed\" target=\"_blank\" id=\"17973966\">17973966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25769073\"></a>Whited LK, Latran MJ, Hashmi ZA, et al. Evaluation of Alemtuzumab Versus Basiliximab Induction: A Retrospective Cohort Study in Lung Transplant Recipients. <i>Transplantation</i>. 2015;99(10):2190-2195.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/25769073/pubmed\" target=\"_blank\" id=\"25769073\">25769073</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Willis F, Marsh JC, Bevan DH, et al, &ldquo;The Effect of Treatment With Campath-1H in Patients With Autoimmune Cytopenias,&rdquo; <i>Br J Haematol</i>, 2001, 114(4):891-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/11564082/pubmed\" target=\"_blank\" id=\"11564082\">11564082</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wolff D, Schleuning M, von Harsdorf S, et al, &ldquo;Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-Versus-Host Disease,&rdquo; <i>Biol Blood Marrow Transplant</i>, 2011, 17(1):1-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alemtuzumab-drug-information/abstract-text/20685255/pubmed\" target=\"_blank\" id=\"20685255\">20685255</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8725 Version 165.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708604\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F26536170\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F4663229\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F131201\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F131179\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F50944438\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F131180\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15671340\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15671341\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F26340642\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F131202\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F26536171\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F131144\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F24943496\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F14944659\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F26619137\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F131160\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F131159\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475021\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3401548\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F131150\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F131163\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F131148\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298700\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F2139162\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F131154\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F131165\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F131166\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F131156\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F131147\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F131162\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F26597090\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F131167\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8725|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=alemtuzumab-patient-drug-information\" class=\"drug drug_patient\">Alemtuzumab: Patient drug information</a></li></ul></div></div>","javascript":null}